NICE To Recommend AZ's Lynparza After All
This article was originally published in Scrip
Executive Summary
AstraZeneca has managed to provide the necessary evidence for NICE, the health technology appraisal institute for England and Wales, to say yes to its PARP inhibitor Lynparza (olaparib) for a patient subpopulation with BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer. Earlier this year NICE looked set to reject the drug.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.